Asset Management Company focuses on early to late stage technology based companies in both the information technology and life science sectors. Although the majority of companies we fund are based in Northern California, we make investments throughout the United States, Europe and Asia. We often invest and work closely with our global affiliate partners.
AMC seeks opportunities where our skills, experience and relationships will contribute meaningfully to a company's success. Our team becomes trusted and valued partners to entrepreneurs. Building successful growth companies and creating substantial equity value are AMCs two goals. Our investment profile includes seed funding, growth financings, and later stage VIPE investments.
Health Sciences Technology ("HST")
Increased bandwidth, improved communications and faster processing power combined with regulatory changes, increased medical costs and changing demographics are disruptive forces in the health care industry. AMC is interested in the area of health sciences technology ("HST") HST which we define as the confluence of technology, biology and health information. Some areas of interest are:
- Electronic Health Records
- Communications and mobile health
- Imagining and visualization
- Personalized medicine and genomics
- e-billing and insurance
- Informatics, data mining and simulation
- Monitoring and compliance
- Web-based social media
- Materials and devices
- Monitoring and compliance
We look for companies that have core technology that addresses problems in extremely large markets with explosive growth. Such firms are likely to focus on:
- Telecommunications
- Automation solutions
- Computer hardware
- Computer software
- Networking
- Internet business applications & information services
- Mobility and wireless applications and infrastructure
- Databases and Datacenter management
- Nanotechnology
- Energy and environmental technologies
In spite of the fact that remarkable technological advances in the treatment of many diseases have been made over the last several decades, millions of patients continue to suffer from illnesses that are unsatisfactorily or inadequately treated.
Our team will consider investments in the healthcare sector, broadly defined. We generally prefer "product model" companies, but will also consider novel platform technologies.
We are especially interested in:
- Emerging Pharmaceuticals (small molecule therapeutics, biopharmaceuticals and cell therapy)
- Medical devices